Senders Pediatrics

South Euclid, Ohio 44121

5 studies enrolling now · 23 studies all time

What they study most

COVID-19, Cytomegalovirus Infection, Epstein-Barr Virus Infection, Healthy, Healthy Participants, Influenza, Meningococcal Vaccine, Pneumococcal Disease, Pneumococcal Infections, Pneumococcal Vaccines, RESPIRATORY SYNCYTIAL VIRUS (RSV), Respiratory Syncytial Virus

Studies at this site

• BEATRIX: A Study to Learn About a Group B Streptococcus Vaccine in Healthy Pregnant Women and Their Babies — Recruiting now
• Study to Learn About Safety, Tolerability, and Immune Response of a Catch-up Pneumococcal Vaccine in Children and Adolescents — Recruiting now
• A Study to Learn About How a New Pneumococcal Vaccine Works in Infants. — Recruiting now
• A Study to Learn About the Safety of an Expanded Pneumococcal Vaccine in Healthy Infants — Recruiting now
• A Study to Learn About a Vaccine Against E Coli in Healthy Adults — Recruiting now
• A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That Are Considered at Higher Risk of Severe COVID-19 — Completed
• A Study to Learn About How a New Pneumococcal Vaccine Works in Infants — Running, not enrolling
• A Study to Learn About COVID-19 RNA-Based Variant-Adapted Vaccine Candidate(s) Against SARS-CoV-2 in Participants Ages 12 Through 64 Years Considered at Higher Risk of Severe COVID-19, and Participants Ages ≥65 Years — Completed
• Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Children — Completed
• Study to Evaluate Safety and Immunogenicity of COVID-19 Vaccine in Children 6 Months to < 12 Years — Completed
• A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 in Healthy Infants — Running, not enrolling
• A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults — Running, not enrolling
• A Study to Learn About New COVD-19 RNA Vaccine Candidates for New Variants in Healthy Individuals — Completed
• Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals — Completed
• A Study to Learn About How a New Pneumococcal Vaccine Works in Children — Completed
• A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age — Stopped early
• To Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of BNT162b2 Boosting Strategies Against COVID-19 in Participants ≥12 Years of Age. — Completed
• A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus — Completed
• Comparative Immunogenicity of Concomitant vs Sequential mRNA COVID-19 and Influenza Vaccinations — Completed
• A Study to Learn About the Safety and Immune Activity of RSVpreF in Children 2 to <18 Years of Age — Completed
• 20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 4-Dose Series in Healthy Infants — Completed
• MenABCWY Noninferiority Study in Healthy Participants ≥10 to <26 Years of Age — Completed
• Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Vaccine in Healthy Infants — Completed